Anything in the genomic medicine space, that is to say, the ARKG etf.
A lot of new opportunities opened up in this field recently due to crispr, and they haven’t been realized yet, and the stocks are generally too low due to, I dunno, Theranos maybe. Some of the treatments are really amazing. Cures for previously incurable genetic diseases, better cancer treatments.
We should pause, though, and ask whether accelerating the realization of these technologies will accelerate the realization of extinctive biological weapons. I have not paused long enough over this question, myself. I can’t really argue that the benefits outweigh the costs.